Prof. Erika Lietzan

Professor Lietzan Speaks at Conference about New Uses of Established Drugs

February 14th, 2018

On February 8, Professor Erika Lietzan spoke at the conference, “Clinical Innovation: Fair and Effective Incentives for New Uses of Established Drugs,” convened in Washington, DC, by University College London (UCL) and the Georgetown University Law Center (GULC). This

Read More

Professor Lietzan Presents Research Examining Impact of Pharmaceutical Regulation

January 4th, 2018

In December, Professor Erika Lietzan spoke at a pharmaceutical law conference hosted by the CREDIMI, a center for research relating to markets and international investment, at the school of law at the Université de Bourgogne in Dijon,

Read More

Professor Lietzan Speaks on Panel at Supreme Court IP Review

November 6th, 2017

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June.

Read More

Pan American Journal of Public Health Publishes Letter from Professor Lietzan

October 13th, 2017

The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for

Read More

Professor Lietzan Named Best Lawyer in FDA Law and Biotechnology Law

August 23rd, 2017

Professor Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology Law. This marks the fifth year in a row for FDA Law and the eleventh year in a row for

Read More